Ascelia Pharma – What developed during Q1?

Meet and ask questions to CEO Magnus Corfitzen from Ascelia Pharma when he briefs the investor community about activities from Q1 2023 – Thursday the 11th of May from 12:00 to 12:30 CEST.

Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia Pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detection and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a phase 2 study with an estimated completion date in 2024. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult-to-treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement. Claus Thestrup 09:59 CEST – 04/26/2023.